Comparing carbon emissions from oral tenofovir disoproxil fumarate/emtricitabine for preexposure prophylaxis and long-acting injectables for HIV prevention Authors: Kiran Rodrigues, Ramine Bahrambegi, Michael Reid Published: 2026 ABSTRACT AbstractEstimated greenhouse gas emissions from active pharmaceutical ingredient (API) production were compared for oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and long-acting injectable preexposure prophylaxis (PrEP) agents, cabotegravir (CAB-LA) and lenacapavir (LEN). For 2 million person-years of PrEP, TDF/FTC generated approximately 108 million kg CO2e, compared with 4.1 million kg for CAB-LA and less than 0.1 million kg for LEN. These findings suggest substantially lower emissions with long-acting agents, supporting consideration of environmental sustainability in HIV prevention strategies. Introduction As the global health community confronts the dual imperatives of advancing public health and mitigating climate change, the environmental sustainability of health interventions is receiving growing attention [1]. Yet the climate impact of HIV prevention strategies – particularly the greenhouse gas (GHG) emissions associated with the production and distribution of pharmaceutical commodities – remains underexplored. Daily oral preexposure prophylaxis (PrEP) regimens, such as tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), are an important biomedical HIV prevention modality in many settings with high HIV burden [2]. Recent estimates suggest that up to 89% of TDF/FTC's GHG emissions stem from the production of active pharmaceutical ingredients (APIs), while for newer agents like cabotegravir long-acting (CAB-LA), API production accounts for approximately 66% of total emissions [3]. This research letter examines the environmental implications of LAI PrEP by focusing on GHG emissions associated exclusively with API production. Methods We estimated GHG emissions associated with the production of API for three PrEP formulations: oral TDF/FTC, long-acting cabotegravir (CAB-LA), and lenacapavir (LEN). Because standardized lifecycle data for injectable administration in LMICs are not consistently available, the analysis focuses specifically on API production, the largest contributor to pharmaceutical emissions, rather than the full delivery lifecycle. Emissions were estimated using a 2 million person-year benchmark, reflecting the joint PEPFAR–Global Fund commitment to deliver 2 million person-years of PrEP between 2026 and 2028 [4]. API emissions factors – expressed as kilograms of carbon dioxide equivalent (kg CO2e) per kilogram of API – were drawn from proprietary analyses provided by Unitaid [3] and supplemented through expert consultations with Gilead technical staff. For TDF/FTC, the API emission factor was estimated at 295.4 kg CO2e/kg API, derived from Unitaid's reported values for tenofovir (367 kg CO2e/kg API) and lamivudine (188 kg CO2e/kg API) (we treated lamivudine (3TC) and emtricitabine (FTC) as synthetically equivalent for GHG modeling; as FTC is the 5-fluorinated derivative of the 3TC scaffold and both utilize an identical (-) L-enantiomer oxathiolane configuration, their core manufacturing pathways and energy intensities are considered uniform) [5]. For CAB-LA, the emission factor was estimated at 572 kg CO2e/kg API [3] and for LEN, estimated to be 11.1 kg CO2e/kg API (personal communication, 2025). Annual per-person API consumption was calculated as 182.5 g for daily oral TDF/FTC (500 mg/day), 3.6 g for CAB-LA (600 mg every 2 months), and 3.981 g for LEN [927 mg every 6 months plus oral lead in dose (2127 mg) at treatment initiation]. Total emissions for each product were then derived by multiplying API mass by the relevant emission factor and scaling to 2 million person-years. Sensitivity analyses modeled three scale-up scenarios for CAB-LA and LEN adoption (12.5, 25, and 50 of the 2 million person-years), assuming a corresponding reduction in TDF/FTC use. Emissions from packaging, storage, distribution, and clinic-based delivery were not included in this analysis but are likely to be substantial across all PrEP modalities, highlighting the need for further investigation in future studies. Results Across the 2 million person-years benchmark used in this analysis, oral TDF/FTC is estimated to generate 107.8 million kg of carbon dioxide equivalent (CO2e) emissions. In contrast, CAB-LA and LEN are estimated to generate 4.1 million kg and 88 378 kg CO2e, respectively (Table 1). This represents a greater than 96% reduction in emissions when transitioning from TDF/FTC to CAB-LA and a more than 99.9% reduction when transitioning to LEN. Table 1Estimated active pharmaceutical ingredient-related CO2 emissions for 2 million person-years of HIV prevention.RegimenDose per year (mg)API per person-year (kg)Kilograms of CO2e per kg APITotal CO2e emissions (kg)TDF/FTC182 5000.1825295.4107 821 000CAB-LA36000.00365724 118 400LEN39810.00398111.188 378.2Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and cabotegravir (CAB-LA) emission factor based on Unitaid report. Lenacapavir (LEN) emissions estimated based on new manufacturer data showing a 26-fold lower CO2e per kg API compared to TDF/FTC. API, active pharmaceutical ingredient; CO2e, carbon dioxide equivalent. Estimated active pharmaceutical ingredient-related CO2 emissions for 2 million person-years of HIV prevention. Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and cabotegravir (CAB-LA) emission factor based on Unitaid report. Lenacapavir (LEN) emissions estimated based on new manufacturer data showing a 26-fold lower CO2e per kg API compared to TDF/FTC. API, active pharmaceutical ingredient; CO2e, carbon dioxide equivalent. Scenario analyses of CAB-LA adoption at different uptake levels –12.5, 25, and 50% – were conducted to reflect more realistic implementation pathways. At 12.5% CAB-LA uptake, the estimated reduction in GHG emissions was approximately 12%, rising to 24% with 25% uptake and 48% with 50% uptake (Table S1). Notably, if this scale-up strategy were to include LEN, overall emissions reductions would likely be even greater, as LEN's CO2e per person-year is over 45 times lower than TDF/FTC and similar to CAB-LA. Thus, these projections may be considered conservative estimates of the potential environmental benefit of transitioning to LAI PrEP. Discussion Based on current emission factors for API production, our estimates indicate that delivering 2 million person-years of HIV prevention would generate over 107 million kg of CO2e with oral TDF/FTC, compared to approximately 4.1 million kg with CAB-LA and approximately 41 000 kg with LEN. These differences point to the potential for LAI products to achieve measurable API-related GHG reductions. Even a gradual transition from oral PrEP to LAI would have a substantial impact on GHG. Moreover, our analysis offers a practical model for integrating environmental metrics into HIV policy discussions and highlights the opportunity to align sustainability goals with efforts to scale new prevention tools in high-burden settings [6]. Nonetheless, the analysis has several limitations. First, the emissions estimates focus solely on API production and exclude emissions from transportation, logistics, clinic visits, and packaging, which may be more substantial for injectable regimens [7]. Second, LEN estimates are based on early manufacturer data, and real-world emissions could vary depending on production scale, sourcing, and formulation. Third, our analysis does not evaluate cost-effectiveness in financial terms. While the environmental cost of carbon emissions is real, its monetary impact remains outside the scope of the study. Future studies should consider both the economic and environmental value of prevention commodities to better inform procurement and policy decisions. Finally, while these initial results underscore the importance of incorporating environmental impact into a broader framework for evaluating HIV prevention options, it is important to recognize that governments in high-burden countries face numerous competing priorities. It remains unclear to what extent greenhouse gas emissions factor into decision-making when weighed against more immediate concerns, such as health workforce shortages, unmet treatment needs, or supply chain inefficiencies. Moreover, they do not provide any insight into the political will to invest in climate-responsive HIV programs from donors or partner governments. Conclusion As global health programs navigate a rapidly changing landscape – defined by fiscal constraints, climate threats, and the need for greater efficiency – long-acting injectable HIV prevention tools offer a promising path forward. The dramatic reductions in carbon emissions associated with CAB-LA and LEN provide a powerful argument for integrating sustainability into HIV prevention strategies. Acknowledgements Conflicts of interest There are no conflicts of interest. Supplementary Material Supplemental Digital Content Footnotes Supplemental digital content is available for this article. References Associated Data Supplementary Materials Supplemental Digital Content